Business Context and Reporting Period
Company: Baxter International Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2001
Business Overview: Baxter operates in three primary segments: Medication Delivery (infusion pumps, solutions, anesthesia), BioScience (biopharmaceuticals, blood collection), and Renal (kidney disease treatment). The company is a global manufacturer of medical products and services.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Sep 30, 2001 | 9 Months Ended Sep 30, 2001 | 9 Months Ended Sep 30, 2000 |
|---|---|---|---|
| Net Sales | $1,900 | $5,527 | $4,964 |
| Net Income | $272 | $687 | $470 |
| Diluted EPS | $0.45 | $1.13 | $0.79 |
| Cash Flow from Operations | N/A | $361 | $447 |
| Capital Expenditures | N/A | ($493) | ($398) |
| Cash and Equivalents | $470 | $470 | $568 |
| Total Debt (Short + Long Term) | $618 | $618 | $2,360 |
| Gross Margin | 45.0% | 44.4% | 44.2% |
Note: Total Debt for 2000 includes $576M short-term and $1,726M long-term. 2001 includes $522M short-term and $2,576M long-term.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% for the quarter and 11% for the nine-month period compared to 2000. Excluding currency fluctuations, sales growth was 16% for both periods.
- Profitability: Net income rose 18% for the quarter and 46% for the nine-month period. This increase was driven by strong sales growth in BioScience and Medication Delivery segments and improved cost management.
- Accounting Changes: The adoption of SFAS No. 133 (Derivatives) resulted in a one-time cumulative effect charge of $52 million (net of tax) in the first quarter of 2001, reducing net income for the nine-month period.
- Acquisitions: Significant acquisitions included Cook Pharmaceutical Solutions ($220M) and Sera-Tec Biologicals ($127M), contributing to sales and goodwill increases.
- Cash Flow: Operating cash flow decreased to $361 million (from $447 million in 2000) due to increases in accounts receivable and inventory, partially offset by higher earnings.
Outlook, Risks, and Unusual Items
- Subsequent Acquisition: On October 30, 2001, Baxter acquired ASTA Medica Onkologie GmbH for approximately $470 million. A substantial portion of the purchase price is expected to be allocated to in-process R&D and expensed immediately.
- Product Recall and Charge: Following reports of patient deaths in Croatia linked to A series dialyzers, Baxter initiated a global recall and permanently ceased manufacturing these products. The company expects a fourth-quarter 2001 after-tax charge of $100 million to $150 million, with a cash impact estimated at no more than $50 million.
- Legal Contingencies: Significant ongoing litigation includes mammary implant claims (346 lawsuits pending) and plasma-based therapy claims (HIV/Hepatitis C infections). Management believes reserves are adequate but acknowledges potential for future charges.
- Guidance: Management expects full-year 2001 R&D expense growth to be in the low double digits. The effective tax rate is expected to remain stable for the remainder of the year.
- Market Risk: The company faces exposure to currency fluctuations (Euro, Yen, Pound, Franc) and interest rate changes. A 10% unfavorable fluctuation in the USD could decrease the fair value of hedging contracts by approximately $237 million.
Investor Verification Checklist
- Dialyzer Recall Impact: Verify the final magnitude of the $100M-$150M charge and the extent of the cash outflow related to the A series dialyzer recall.
- ASTA Acquisition Accounting: Confirm the final purchase price allocation for the ASTA acquisition, specifically the amount expensed as in-process R&D.
- Working Capital Trends: Monitor the continued growth in accounts receivable and inventory, which negatively impacted operating cash flow in the first nine months.
- Legal Reserves: Review updates on mammary implant and plasma-based therapy litigation to ensure reserves remain sufficient against potential settlements.
- Currency Hedging: Assess the impact of a strengthening US dollar on future international sales growth, as currency headwinds reduced reported growth rates.